6th ESOU Meeting

December 16, 2008

The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in Istanbul, Turkey, from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists.

With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologists, scientists and researchers the opportunity to explore the various options that will enable cancer specialists to identify optimal treatment approaches.

"The ESOU is - and intends to remain - one of the most important platforms of scientific information exchange among experts as well as professionals interested in the field. It will continue to serve as a key opinion leader and promote the dissemination of high-quality uro-oncological scientific information, in order to increase the quality of medical service," said ESOU Chairman Prof. Vincent Ravery (Paris, France).

The most common malignancies such as prostate cancer (PCa), renal cell carcinoma and bladder cancer were the focus of last year's meeting in Berlin. Apart from these conditions, testis cancer will be another highlight of the forthcoming meeting in Istanbul.

Prof. Levent Türkeri (Istanbul, Turkey), ESOU board member and local organiser said: "On Friday, 16 January, an interesting pro-contra debate is organised entitled 'Should hormones (adjuvant/neo-adjuvant) be dedicated to radiotherapy and abandoned in patients to be treated with surgery?' Furthermore, the lecture by Prof. Theo de Reijke of the European Organisation on the Research and Treatment of Cancer-Genitourinary Group (Update on the recent data retrieved from EORTC GU group studies) deserves attention."

The introduction of targeted therapies, which will be discussed during the sessions on renal cell carcinoma, meant a revolution in the field of oncology in general. These therapies appear to evolve into the mainstay of medical treatment of malignancies of the urogenital tract and are likely to convert the disease from a progressive and lethal one into a chronic, controllable process in many cases.
-end-
Established in 2001, the ESOU, a full member of the EAU Section Office, organises two meetings every year, one of them during the EAU congress, with the first meeting held in January. Approximately 500 participants are expected in Istanbul. The 6th ESOU Meeting is also accredited within the EU-ACME programme by the European Board of Urology (EBU).

For more information, please contact esou2009@congressconsultants.com or visit www.uroweb.org.

European Association of Urology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.